Amneal director reports 283,632-share award
Amneal Pharmaceuticals, Inc. director Gautam Patel reported an indirect acquisition of 283,632 shares of Class A common stock on August 10, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Amneal Pharmaceuticals, Inc. director Gautam Patel reported an indirect acquisition of 283,632 shares of Class A common stock on August 10, 2026. The shares were received by limited liability companies managed by him as part of Amneal’s acquisition of Kashiv BioSciences, LLC. Following this transaction, he also reported 1,643,963 shares held directly.
Insider Trade Summary
Grant/Award: 283,632 shares
Grant/Award
2 txns
Insider
Patel Gautam
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Class A Common Stock F1 | 283,632 | -- | -- |
| holding | Class A Common Stock | -- | -- | -- |
Holdings After Transaction:
Class A Common Stock — 283,632 shares (Indirect, By Limited Liability Company);
Class A Common Stock — 1,643,963 shares (Direct)
Footnotes (1)
- F1. On August 10, 2026, pursuant to a Membership Interest Purchase Agreement, dated as of April 21, 2026 (as amended from time to time, the Purchase Agreement), by and among the Issuer, Kashiv BioSciences, LLC (Kashiv), KB Seller Representative, LLC and the equity holders of Kashiv named therein (the Sellers), a subsidiary of the Issuer purchased (the Acquisition) from the Sellers 100% of the issued and outstanding membership interests of Kashiv for an aggregate consideration of $375,000,000 in cash, subject to certain purchase price adjustments, and 28,942,098 shares of Issuer Class A common stock (Class A Common Stock). Pursuant to the terms of the Purchase Agreement, limited liability companies managed by the Reporting Person received 283,632 shares of Class A Common Stock in the Acquisition.
Key Figures
Indirect shares acquired: 283,632 shares
Direct holdings after transaction: 1,643,963 shares
Cash consideration for Kashiv: $375,000,000
+2 more
5 metrics
Indirect shares acquired
283,632 shares
Class A common stock received by LLCs managed by Gautam Patel in the acquisition
Direct holdings after transaction
1,643,963 shares
Class A common stock held directly by Gautam Patel following the reported transaction
Cash consideration for Kashiv
$375,000,000
Cash portion of aggregate consideration to purchase 100% of Kashiv BioSciences’ membership interests
Stock consideration for Kashiv
28,942,098 shares
Amneal Class A common stock issued as part of consideration in the Kashiv BioSciences acquisition
Kashiv interest acquired
100%
Percentage of issued and outstanding membership interests of Kashiv BioSciences purchased
Key Terms
Membership Interest Purchase Agreement, purchase price adjustments, aggregate consideration, Class A Common Stock, +1 more
5 terms
Membership Interest Purchase Agreement regulatory
"pursuant to a Membership Interest Purchase Agreement, dated as of April 21, 2026"
A membership interest purchase agreement is a contract used when someone buys an ownership stake in a limited liability company (LLC). It spells out what is being sold, the price, any promises about the business’s condition, and who takes responsibility for debts or legal issues—like a receipt and rulebook for the sale. Investors care because it transfers control, affects future cash flow and liabilities, and can change the value and tax treatment of their investment.
purchase price adjustments financial
"for an aggregate consideration of $375,000,000 in cash, subject to certain purchase price adjustments"
Purchase price adjustments are changes made to the agreed sale price of a company after closing to reflect actual financial facts—like cash on hand, debts, or inventory—found when final accounts are prepared. Think of it as the final bill after a home inspection: the buyer and seller settle differences so the price matches reality. For investors, these adjustments affect the true cost, future earnings and cash flow from a deal, and therefore the value of the investment.
aggregate consideration financial
"for an aggregate consideration of $375,000,000 in cash"
Class A Common Stock financial
"28,942,098 shares of Issuer Class A common stock (Class A Common Stock)"
Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.
limited liability companies regulatory
"limited liability companies managed by the Reporting Person received 283,632 shares"
A limited liability company (LLC) is a business structure that separates the owners’ personal assets from the company’s liabilities, like a protective shield that limits how much owners can lose if the business gets into debt or legal trouble. It matters to investors because an LLC affects who bears risk, how profits are taxed (either at the company or passed to owners’ personal tax returns), and how easily ownership can be bought, sold, or reorganized.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Amneal (AMRX) director Gautam Patel report on August 10, 2026?
Gautam Patel reported an indirect acquisition of 283,632 Class A shares of Amneal Pharmaceuticals. The shares were issued to limited liability companies he manages in connection with Amneal’s acquisition of Kashiv BioSciences, LLC.
What were the overall terms of Amneal’s acquisition of Kashiv BioSciences mentioned in this Form 4?
A subsidiary of Amneal purchased 100% of Kashiv BioSciences for $375,000,000 in cash, subject to purchase price adjustments, plus 28,942,098 Class A shares of Amneal as stock consideration under a Membership Interest Purchase Agreement.
Was Gautam Patel’s Amneal (AMRX) Form 4 transaction a market purchase or sale?
No market purchase or sale is reported. The filing shows a grant/award-type acquisition of 283,632 shares received by entities he manages as part of Amneal’s stock consideration in acquiring Kashiv BioSciences.
AI-generated analysis. How Rhea-AI works. Not financial advice.
